Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Borderline ovarian tumors

Lee-may Chen, MD
Jonathan S Berek, MD, MMS
Section Editors
Barbara Goff, MD
Don S Dizon, MD, FACP
Deputy Editors
Sandy J Falk, MD, FACOG
Sadhna R Vora, MD


Borderline tumors of the ovary (also called tumors of low-malignant potential) are a heterogeneous group of lesions defined histologically by atypical epithelial proliferation without stromal invasion [1]. The behavior of these tumors is distinct from low-grade ovarian carcinoma and they are considered a distinct clinical entity.

The epidemiology, diagnosis, and treatment of borderline ovarian tumors are reviewed here. Ovarian cancer is discussed separately. (See "Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum" and "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors" and "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis" and "Cancer of the ovary, fallopian tube, and peritoneum: Staging and initial surgical management" and "First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer".)


Borderline ovarian epithelial neoplasms are non-invasive neoplasms that occasionally have intraperitoneal spread [2]. This group of neoplasms exhibit behavior that is intermediate between benign cystadenomas and invasive carcinomas. These have been referred to by different terms, including: borderline, atypical proliferative, and tumors of low-malignant potential. Borderline neoplasm is currently the most widely used designation by pathologists, gynecologists, and oncologists, and has been adopted into the World Health Organization classification [3].

Borderline tumors account for 14 to 15 percent of all primary ovarian neoplasms [4].

Borderline tumors occur in a variety of histologies, as in epithelial ovarian carcinoma [5,6]. The majority of cases are serous or mucinous. Rarely, endometrioid, clear-cell, or transitional cell (Brenner) borderline tumors are found.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jun 17, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Blaustein's pathology of the female genital tract, 5th, Kurman RJ (Ed), Springer Verlag, New York 2002. p.791.
  2. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003; 17:909.
  3. Karseladze AI. [WHO histological classification of ovarian tumors. Geneva, 1999 (R.E.Scully, L.H.Sobin]. Arkh Patol 2005; Suppl:1.
  4. Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer 2008; 123:1897.
  5. Trimble CL, Trimble EL. Ovarian tumors of low malignant potential. Oncology (Williston Park) 2003; 17:1563.
  6. Harter P, Gershenson D, Lhomme C, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 2014; 24:S5.
  7. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol 2005; 18 Suppl 2:S33.
  8. Jones MB. Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 2006; 49:517.
  9. Pecorelli S, Odicino F, Maisonneuve P, et al. FIGO annual report of the results of treatment in gynaecological cancer. Carcinoma of the ovary. J Epidemiol Biostat 1998; 3:75.
  10. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19:2658.
  11. Tinelli R, Tinelli A, Tinelli FG, et al. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 2006; 100:185.
  12. Sood AK, Abu-Rustum NR, Barakat RR, et al. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol 2005; 97:916.
  13. Lazarou A, Fotopoulou C, Coumbos A, et al. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors. Anticancer Res 2014; 34:6725.
  14. Seidman JD, Ronnett BM, Kurman RJ. Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol 2002; 16:499.
  15. Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998. Cancer 2002; 95:2380.
  16. Hannibal CG, Huusom LD, Kjaerbye-Thygesen A, et al. Trends in incidence of borderline ovarian tumors in Denmark 1978-2006. Acta Obstet Gynecol Scand 2011; 90:305.
  17. Yahata T, Banzai C, Tanaka K, Niigata Gynecological Cancer Registry. Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata. J Obstet Gynaecol Res 2012; 38:645.
  18. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002; 155:217.
  19. Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Database Syst Rev 2013; :CD008215.
  20. Bjørnholt SM, Kjaer SK, Nielsen TS, Jensen A. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study. Hum Reprod 2015; 30:222.
  21. Bjørge T, Lie AK, Hovig E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer 2004; 91:1829.
  22. Maehle L, Apold J, Paulsen T, et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin Cancer Res 2008; 14:7569.
  23. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807.
  24. Gotlieb WH, Chetrit A, Menczer J, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol Oncol 2005; 97:780.
  25. Mørch LS, Løkkegaard E, Andreasen AH, et al. Hormone therapy and ovarian borderline tumors: a national cohort study. Cancer Causes Control 2012; 23:113.
  26. Mills PK, Riordan DG, Cress RD, Goldsmith DF. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 2005; 29:124.
  27. Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001; 83:575.
  28. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004; 291:2705.
  29. Exacoustos C, Romanini ME, Rinaldo D, et al. Preoperative sonographic features of borderline ovarian tumors. Ultrasound Obstet Gynecol 2005; 25:50.
  30. Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol 2004; 18:71.
  31. Valentin L, Ameye L, Testa A, et al. Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol 2006; 102:41.
  32. Yazbek J, Raju KS, Ben-Nagi J, et al. Accuracy of ultrasound subjective 'pattern recognition' for the diagnosis of borderline ovarian tumors. Ultrasound Obstet Gynecol 2007; 29:489.
  33. Ochiai K, Shinozaki H, Takada A, et al. A retrospective study of 1069 epithelial borderline malignancies of the ovary treated in Japan. Proceedings of the Annual Meeting of the American Society of Clinical Oncology 1998; 17:A1429.
  34. Geomini P, Bremer G, Kruitwagen R, Mol BW. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol 2005; 96:1.
  35. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000; 31:539.
  36. Lesieur B, Kane A, Duvillard P, et al. Prognostic value of lymph node involvement in ovarian serous borderline tumors. Am J Obstet Gynecol 2011; 204:438.e1.
  37. Boran N, Cil AP, Tulunay G, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecol Oncol 2005; 97:845.
  38. Morice P, Camatte S, El Hassan J, et al. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil Steril 2001; 75:92.
  39. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol 2006; 103:841.
  40. Ayhan A, Celik H, Taskiran C, et al. Oncologic and reproductive outcome after fertility-saving surgery in ovarian cancer. Eur J Gynaecol Oncol 2003; 24:223.
  41. Daraï E, Fauvet R, Uzan C, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 2013; 19:151.
  42. Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988; 72:775.
  43. Yokoyama Y, Moriya T, Takano T, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 2006; 94:1586.
  44. Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 2002; 16:513.
  45. Fauvet R, Boccara J, Dufournet C, et al. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer 2004; 100:1145.
  46. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree#site (Accessed on March 20, 2015).
  47. Palomba S, Zupi E, Russo T, et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum Reprod 2007; 22:578.
  48. Desfeux P, Camatte S, Chatellier G, et al. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol Oncol 2005; 98:390.
  49. Fauvet R, Boccara J, Dufournet C, et al. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 2005; 16:403.
  50. Maneo A, Vignali M, Chiari S, et al. Are borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol 2004; 94:387.
  51. Tropé C, Kaern J, Vergote IB, et al. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993; 51:236.
  52. Fort MG, Pierce VK, Saigo PE, et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989; 32:269.
  53. Barakat RR, Benjamin I, Lewis JL Jr, et al. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995; 59:390.
  54. Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991; 41:230.
  55. Shih KK, Zhou QC, Aghajanian C, et al. Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol 2010; 119:270.
  56. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273:491.
  57. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).
  58. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.
  59. Fauvet R, Poncelet C, Boccara J, et al. Fertility after conservative treatment for borderline ovarian tumors: a French multicenter study. Fertil Steril 2005; 83:284.
  60. Chan JK, Lin YG, Loizzi V, et al. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J Reprod Med 2003; 48:756.
  61. Beiner ME, Gotlieb WH, Davidson B, et al. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 2001; 92:320.
  62. Seracchioli R, Venturoli S, Colombo FM, et al. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil Steril 2001; 76:999.
  63. Camatte S, Morice P, Pautier P, et al. Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary. BJOG 2002; 109:376.
  64. Donnez J, Munschke A, Berliere M, et al. Safety of conservative management and fertility outcome in women with borderline tumors of the ovary. Fertil Steril 2003; 79:1216.
  65. Tinelli FG, Tinelli R, La Grotta F, et al. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors. Acta Obstet Gynecol Scand 2007; 86:81.
  66. Marcickiewicz J, Brännström M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence. Acta Obstet Gynecol Scand 2006; 85:1496.
  67. Fasouliotis SJ, Davis O, Schattman G, et al. Safety and efficacy of infertility treatment after conservative management of borderline ovarian tumors: a preliminary report. Fertil Steril 2004; 82:568.
  68. Fortin A, Morice P, Thoury A, et al. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 2007; 87:591.
  69. Morice P, Camatte S, Rey A, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol 2003; 14:592.
  70. Gershenson DM. Is micropapillary serous carcinoma for real? Cancer 2002; 95:677.
  71. Kaern J, Tropé CG, Kristensen GB, et al. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993; 3:349.
  72. Buttin BM, Herzog TJ, Powell MA, et al. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002; 99:11.
  73. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005; 29:707.
  74. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002; 86:34.
  75. Crispens MA, Bodurka D, Deavers M, et al. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet Gynecol 2002; 99:3.
  76. Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992; 47:150.
  77. Bostwick DG, Tazelaar HD, Ballon SC, et al. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 1986; 58:2052.
  78. Bristow RE, Gossett DR, Shook DR, et al. Recurrent micropapillary serous ovarian carcinoma. Cancer 2002; 95:791.
  79. Zang RY, Yang WT, Shi DR, et al. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients. J Surg Oncol 2005; 91:67.